organization · Reporting owner
InvaGen Pharmaceuticals, Inc.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AVENUE THERAPEUTICS, INC.
Report date October 11, 2022 · Filed October 13, 2022
Section 16 reporting ended · disclosed 2022-10-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-11 transaction · row 1
1 source rowRow 1 · 2022-10-11 · Sale · Disposed 388,888 · Balance 0 F1: This Form 4 is being jointly filed on behalf of (i) InvaGen Pharmaceuticals Inc., a New York corporation ("InvaGen"), (ii) Cipla (EU) Limited, a company incorporated in the United Kingdom ("Cipla EU"), and (iii) Cipla Limited, a company incorporated in India ("Cipla Limited") (each of InvaGen, Cipla EU and Cipla Limited, a "Reporting Person", and collectively, the "Reporting Persons"). InvaGen is a wholly-owned direct subsidiary of Cipla EU. Cipla EU is a wholly-owned direct subsidiary of Cipla Limited. Because of the relationship of InvaGen to Cipla EU and Cipla Limited, each such Reporting Person may be deemed to beneficially own the securities covered by this Form 4. F2: On September 22, 2022, the common stock of Avenue Therapeutics, Inc. (the "Issuer") reverse split 1-for-15, resulting in the 5,833,333 shares of common stock of the Issuer previously reported by the Reporting Persons becoming 388,888 shares of common stock of the Issuer. F3: On October 11, 2022, pursuant to the terms of the previously announced Stock Repurchase Agreement, dated July 25, 2022, among InvaGen, Fortress Biotech, Inc. and the Issuer, the Issuer repurchased 388,888 shares of common stock of the Issuer from InvaGen for an aggregate purchase price of $3,000,000 (the "Share Repurchase"). |
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
Holding disclosure · report date 2022-10-11 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 0 F4: As a result of the Share Repurchase and concurrent termination of the Voting and Support Agreement dated November 12, 2018, by and among InvaGen, Madison Pharmaceuticals Inc. and the Issuer, the Reporting Persons no longer have beneficial ownership of the securities previously reported as indirectly owned in the Reporting Persons' Form 3. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 is being jointly filed on behalf of (i) InvaGen Pharmaceuticals Inc., a New York corporation ("InvaGen"), (ii) Cipla (EU) Limited, a company incorporated in the United Kingdom ("Cipla EU"), and (iii) Cipla Limited, a company incorporated in India ("Cipla Limited") (each of InvaGen, Cipla EU and Cipla Limited, a "Reporting Person", and collectively, the "Reporting Persons"). InvaGen is a wholly-owned direct subsidiary of Cipla EU. Cipla EU is a wholly-owned direct subsidiary of Cipla Limited. Because of the relationship of InvaGen to Cipla EU and Cipla Limited, each such Reporting Person may be deemed to beneficially own the securities covered by this Form 4.
F2: On September 22, 2022, the common stock of Avenue Therapeutics, Inc. (the "Issuer") reverse split 1-for-15, resulting in the 5,833,333 shares of common stock of the Issuer previously reported by the Reporting Persons becoming 388,888 shares of common stock of the Issuer.
F3: On October 11, 2022, pursuant to the terms of the previously announced Stock Repurchase Agreement, dated July 25, 2022, among InvaGen, Fortress Biotech, Inc. and the Issuer, the Issuer repurchased 388,888 shares of common stock of the Issuer from InvaGen for an aggregate purchase price of $3,000,000 (the "Share Repurchase").
F4: As a result of the Share Repurchase and concurrent termination of the Voting and Support Agreement dated November 12, 2018, by and among InvaGen, Madison Pharmaceuticals Inc. and the Issuer, the Reporting Persons no longer have beneficial ownership of the securities previously reported as indirectly owned in the Reporting Persons' Form 3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 11, 2022 Filed Oct 13, 2022 20:52 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | SaleCommon Stock, par value $0.0001 per share | 388,888 | $7.71 | $2,999,882.03 |
DisclosureSEC source: 0001104659-22-108589 · tm2228236-1_4seq1.xml · nonDerivative · entry 1 InvaGen Pharmaceuticals, Inc. · CIK 0001759453 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: This Form 4 is being jointly filed on behalf of (i) InvaGen Pharmaceuticals Inc., a New York corporation ("InvaGen"), (ii) Cipla (EU) Limited, a company incorporated in the United Kingdom ("Cipla EU"), and (iii) Cipla Limited, a company incorporated in India ("Cipla Limited") (each of InvaGen, Cipla EU and Cipla Limited, a "Reporting Person", and collectively, the "Reporting Persons"). InvaGen is a wholly-owned direct subsidiary of Cipla EU. Cipla EU is a wholly-owned direct subsidiary of Cipla Limited. Because of the relationship of InvaGen to Cipla EU and Cipla Limited, each such Reporting Person may be deemed to beneficially own the securities covered by this Form 4. F2 · shares: On September 22, 2022, the common stock of Avenue Therapeutics, Inc. (the "Issuer") reverse split 1-for-15, resulting in the 5,833,333 shares of common stock of the Issuer previously reported by the Reporting Persons becoming 388,888 shares of common stock of the Issuer. F3 · price: On October 11, 2022, pursuant to the terms of the previously announced Stock Repurchase Agreement, dated July 25, 2022, among InvaGen, Fortress Biotech, Inc. and the Issuer, the Issuer repurchased 388,888 shares of common stock of the Issuer from InvaGen for an aggregate purchase price of $3,000,000 (the "Share Repurchase"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.